In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities)...
Read More
In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...
Read More
In a nutshell In this work, the authors studied whether VY-AADC01 (NBIb-1817) gene therapy was safe and effective in patients with moderately advanced Parkinson's disease (PD) patients with motor fluctuations. The authors showed that this treatment caused an improvement in motor function, quality of life, and a decrease in the level of...
Read More
In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML). This study concluded that this treatment was safe and effective in the long-term in these...
Read More
In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...
Read More
In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...
Read More
In a nutshell This study investigated whether a single blood pressure (BP) pill containing 4 drugs (quadpill) at quarter doses is more effective than the standard dose of a single drug as initial treatment in patients with hypertension. The data showed that a quadpill was safe and more effective in getting BP under control than the standard...
Read More
In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...
Read More
In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...
Read More
In a nutshell The authors investigated the health-related quality of life (HRQoL) 1 year after the diagnosis of diffuse large B-cell lymphoma (DLBCL). The study found that HRQoL is affected differently in women and men survivors of DLBCL 1 year after diagnosis and that aspects of HRQoL need to be addressed and managed in these...
Read More
In a nutshell This study evaluated the effectiveness and safety of sequential administration of high dose aldesleukin (Interleukin-2; Proleukin) and ipilimumab (Yervoy) in patients with metastatic melanoma. The data showed that high dose aldesleukin and ipilimumab were effective and safe when administered sequentially in these patients. Some background...
Read More
In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) therapy for patients with newly diagnosed multiple myeloma (MM). The data showed that adding daratumumab to the lenalidomide and dexamethasone (Rd) regimen was safe and improved...
Read More
